Katie Remains Ward of the State of Texas!
The saga continues: a judge ruled Thursday that the state of Texas will retain custody of 13-year-old Katie Wernecke, who was taken from her parents after they questioned the need for radiation after chemotherapy. Her chemo had apparently brought her into remission from Hodgkin’s lymphoma. It was later found that the cancer had indeed returned.
Katie will remain with Child Protective Services pending another hearing late next month, juvenile court Judge Carl Lewis ruled. Katie was scheduled to see doctors at M.D. Anderson Cancer Center in Houston on Thursday.
Katie’s parents tried to convince Lewis during a custody hearing that they would not resist efforts to resume her treatment. But he refused to return the girl to their care, noting that Katie’s mother had previously fled with Katie and her father had rejected several doctors’ findings. 449 Articles on the subject
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
